Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

DOI PDF Web Site 36 Citations

Journal

  • Leukemia

    Leukemia 30 (5), 1044-1054, 2016-02-03

    Springer Science and Business Media LLC

Citations (36)*help

See more

Details 詳細情報について

Report a problem

Back to top